Introduction
Alkaptonuria (AKU) is a rare inherited metabolic disorder with severe premature spondyloarthropathy as a major manifestation (Phornphutkul et al. 2002) . Although joint disease is a major feature, virtually all connective tissues are affected leading to a variety of clinical features and complications (Helliwell et al. 2008) . A promising new agent, called nitisinone, is available for the treatment of AKU (McKiernan 2006) . Early nitisinone therapy is likely to prevent morbidity but may only slow or arrest disease progression if started later. Nitisinone is not yet licensed for AKU; therefore, safety is an important issue and potential adverse effects are of interest to those involved in the management of metabolic disorders. Alkaptonuria is a rare inborn error of metabolism characterized by high circulating homogentisic acid (HGA) due to a genetic defect in the enzyme homogentisate dioxygenase (HGD) (Phornphutkul et al. 2002) . The main pathophysiological event is conversion of HGA to a polymeric melanin-like pigment and binding of this pigment to connective tissue, especially cartilage. This process takes many years and is known as ochronosis (Zannoni et al. 1969) . The damaging effects of ochronosis include arthritis (especially in the spine and large weight bearing joints), stones (renal, prostatic, gall bladder and salivary), cardiac valve disease especially aortic (Goodfellow et al. 2005) , ruptures (muscle, tendons and ligaments), osteopenia and fractures (O'Brien et al. 1963) . Virtually all connective tissue is affected.
Nitisinone inhibits p-hydroxyphenyl pyruvate dioxygenase, the enzyme leading to the formation of HGA (Lock et al. 1998) . In keeping with the mode of action of nitisinone, circulating tyrosine increases. The tyrosinaemia that occurs during nitisinone treatment resembles hereditary tyrosinaemia type 3. Adverse effects known to be associated with tyrosinaemia include corneal and dermal toxicity (Meissner et al. 2008) . Therefore, skin rash and dendritic keratopathy might be expected in some patients with a nitisinone-induced tyrosinaemia.
